Status
Conditions
Treatments
About
This is a follow-up study to assess safety and preliminary clinical activity of ADR-001 in patients with liver cirrhosis (Child-Pugh score; Grade B) caused by Hepatitis C or Nonalcoholic Steatohepatitis. Patients who have already participated in the ADR-001-01 study and completed the last evaluation after 24 weeks of administration will be eligible to this study.
Patients registered will continue follow-up observation and evaluate long-term safety and exploratory efficacy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Rohto Pharmaceutical Co., Ltd.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal